Hikma Has An Appetite For More Deals As It Builds On Acquisitions
CEO Siggi Olafsson Discusses Future Deal Targets, Including In Biosimilars
Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.
You may also be interested in...
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Hikma is prepared for additional competitors on key products as well as growing price pressure in the US, CEO Siggi Olafsson tells Generics Bulletin in the second part of an exclusive interview.